{"id":77765,"date":"2026-09-01T12:37:19","date_gmt":"2026-09-01T04:37:19","guid":{"rendered":"https:\/\/flcube.com\/?p=77765"},"modified":"2026-09-01T12:37:19","modified_gmt":"2026-09-01T04:37:19","slug":"nmpa-cde-issues-draft-guideline-to-reduce-or-replace-animal-testing-for-monoclonal-antibodies-opening-public-comment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77765","title":{"rendered":"NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>Center for Drug Evaluation (CDE)<\/strong> of <strong>China<\/strong>&#8216;s <strong>National Medical Products Administration (NMPA)<\/strong> issued the <strong>Guideline for the Reduction or Replacement of Animal Testing for Monoclonal Antibodies (Draft for Comments)<\/strong>, seeking public feedback within one month. The draft establishes a <strong>Weight of Evidence (WoE)<\/strong> framework that could shorten general toxicology requirements for monoclonal antibody programs \u2014 from six months to three months, and in defined circumstances, to full replacement of animal testing \u2014 marking a significant modernization of <strong>China<\/strong>&#8216;s preclinical review standards for biologics.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>Center for Drug Evaluation (CDE)<\/strong> of the <strong>National Medical Products Administration (NMPA)<\/strong><\/td><\/tr><tr><td>Document<\/td><td>Guideline for the Reduction or Replacement of Animal Testing for <strong>Monoclonal Antibodies<\/strong> (Draft for Comments)<\/td><\/tr><tr><td>Scope<\/td><td>Traditional monoclonal antibodies (immunoglobulins with INN suffixes &#8220;-tug&#8221; and &#8220;-bart&#8221;)<\/td><\/tr><tr><td>Decision Framework<\/td><td><strong>Weight of Evidence (WoE)<\/strong> assessment<\/td><\/tr><tr><td>Issued<\/td><td><strong>31 Aug 2026<\/strong><\/td><\/tr><tr><td>Comment Period<\/td><td>One month<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-core-provisions-woe-framework-amp-testing-flexibility\" class=\"wp-block-heading\">Core Provisions \u2014 WoE Framework &amp; Testing Flexibility<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Scope Definition:<\/strong> Applies to traditional monoclonal antibodies (&#8220;-tug&#8221; and &#8220;-bart&#8221; INN suffixes); WoE assessment determines whether animal testing can be reduced or replaced<\/li>\n\n\n\n<li><strong>Reduced Toxicology Pathway:<\/strong> For monoclonal antibodies intended for <strong>non-advanced oncology indications<\/strong>, a <strong>3-month general toxicology study<\/strong> can support a marketing application based on WoE assessment \u2014 versus the conventional <strong>6-month<\/strong> requirement if WoE does not justify reduction<\/li>\n\n\n\n<li><strong>WoE Data Inputs (non-exhaustive):<\/strong>\n<ul class=\"wp-block-list\">\n<li>Target biology (expression profile, physiological\/pathological roles) and predicted toxicity risk<\/li>\n\n\n\n<li>Pharmacological effects (target specificity, mechanism of action) and predicted target-related\/off-target toxicity<\/li>\n\n\n\n<li>Short-term animal toxicity data, PK\/toxicokinetic data, and correlation with clinical adverse reactions<\/li>\n\n\n\n<li>Clinical study data<\/li>\n\n\n\n<li>Study data of monoclonal antibodies targeting the same epitope (if available)<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Non-Animal Methods Encouraged:<\/strong> Scientifically sound, appropriately validated non-animal testing to generate sufficient WoE data is explicitly encouraged<\/li>\n\n\n\n<li><strong>Full Replacement Circumstances:<\/strong> Animal general toxicology testing may be entirely replaced when no relevant animal species exists and non-animal data adequately evaluate toxicity risk, or when accumulated clinical\/non-clinical data on same-epitope monoclonal antibodies demonstrate that animals cannot predict human toxic responses<\/li>\n\n\n\n<li><strong>Residual Safeguard:<\/strong> Under full-replacement scenarios, a short-term exploratory animal study in any relevant or non-relevant species is recommended pre-clinic to assess safety pharmacology, formulation-related safety, and basic pharmacokinetics<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Faster, Cheaper Biologics Development:<\/strong> A WoE-supported 3-month toxicology pathway reduces preclinical cost and timelines for monoclonal antibody sponsors \u2014 a tangible efficiency gain for <strong>China<\/strong>&#8216;s densely populated mAb development landscape<\/li>\n\n\n\n<li><strong>3Rs Alignment with Global Standards:<\/strong> The draft brings <strong>NMPA CDE<\/strong> practice closer to international 3Rs (Replace, Reduce, Refine) momentum, supporting cross-border development strategies and global filing alignment<\/li>\n\n\n\n<li><strong>Same-Epitope Leverage:<\/strong> Recognition of same-epitope data as WoE inputs favors crowded targets where multiple programs exist \u2014 potentially accelerating me-too and follow-on monoclonal antibodies with established clinical precedent<\/li>\n\n\n\n<li><strong>Non-Oncology First, Oncology Watch:<\/strong> The 3-month pathway initially targets <strong>non-advanced oncology indications<\/strong>, with advanced-oncology monoclonal antibodies likely addressed as experience accumulates<\/li>\n\n\n\n<li><strong>Catalyst Watch:<\/strong> The one-month comment window closes in late September; the finalized guideline&#8217;s treatment of WoE thresholds and replacement criteria will set the practical bar for sponsors seeking reduced animal testing<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward-looking assessments of policy impact and development implications that involve risks and uncertainties. The draft guideline is subject to change following public comment. Nothing herein constitutes investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) of China&#8216;s National Medical Products Administration (NMPA) issued the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[102],"class_list":["post-77765","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-cde"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) issued the Guideline for the Reduction or Replacement of Animal Testing for Monoclonal Antibodies (Draft for Comments), seeking public feedback within one month. The draft establishes a Weight of Evidence (WoE) framework that could shorten general toxicology requirements for monoclonal antibody programs \u2014 from six months to three months, and in defined circumstances, to full replacement of animal testing \u2014 marking a significant modernization of China&#039;s preclinical review standards for biologics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77765\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) issued the Guideline for the Reduction or Replacement of Animal Testing for Monoclonal Antibodies (Draft for Comments), seeking public feedback within one month. The draft establishes a Weight of Evidence (WoE) framework that could shorten general toxicology requirements for monoclonal antibody programs \u2014 from six months to three months, and in defined circumstances, to full replacement of animal testing \u2014 marking a significant modernization of China&#039;s preclinical review standards for biologics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77765\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T04:37:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77765#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77765\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment\",\"datePublished\":\"2026-09-01T04:37:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77765\"},\"wordCount\":544,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CDE\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77765#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77765\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77765\",\"name\":\"NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-01T04:37:19+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Guideline for the Reduction or Replacement of Animal Testing for Monoclonal Antibodies (Draft for Comments), seeking public feedback within one month. The draft establishes a Weight of Evidence (WoE) framework that could shorten general toxicology requirements for monoclonal antibody programs \u2014 from six months to three months, and in defined circumstances, to full replacement of animal testing \u2014 marking a significant modernization of China's preclinical review standards for biologics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77765#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77765\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77765#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Guideline for the Reduction or Replacement of Animal Testing for Monoclonal Antibodies (Draft for Comments), seeking public feedback within one month. The draft establishes a Weight of Evidence (WoE) framework that could shorten general toxicology requirements for monoclonal antibody programs \u2014 from six months to three months, and in defined circumstances, to full replacement of animal testing \u2014 marking a significant modernization of China's preclinical review standards for biologics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77765","og_locale":"en_US","og_type":"article","og_title":"NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment","og_description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Guideline for the Reduction or Replacement of Animal Testing for Monoclonal Antibodies (Draft for Comments), seeking public feedback within one month. The draft establishes a Weight of Evidence (WoE) framework that could shorten general toxicology requirements for monoclonal antibody programs \u2014 from six months to three months, and in defined circumstances, to full replacement of animal testing \u2014 marking a significant modernization of China's preclinical review standards for biologics.","og_url":"https:\/\/flcube.com\/?p=77765","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-01T04:37:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77765#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77765"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment","datePublished":"2026-09-01T04:37:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77765"},"wordCount":544,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CDE"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77765#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77765","url":"https:\/\/flcube.com\/?p=77765","name":"NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-01T04:37:19+00:00","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Guideline for the Reduction or Replacement of Animal Testing for Monoclonal Antibodies (Draft for Comments), seeking public feedback within one month. The draft establishes a Weight of Evidence (WoE) framework that could shorten general toxicology requirements for monoclonal antibody programs \u2014 from six months to three months, and in defined circumstances, to full replacement of animal testing \u2014 marking a significant modernization of China's preclinical review standards for biologics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77765#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77765"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77765#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77765"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77765\/revisions"}],"predecessor-version":[{"id":77766,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77765\/revisions\/77766"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}